Page last updated: 2024-10-28

idebenone and Autosomal Dominant Optic Atrophy

idebenone has been researched along with Autosomal Dominant Optic Atrophy in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Romagnoli, M1
La Morgia, C2
Carbonelli, M2
Di Vito, L1
Amore, G1
Zenesini, C1
Cascavilla, ML1
Barboni, P2
Carelli, V2
Smith, TG1
Seto, S1
Ganne, P1
Votruba, M1
Valentino, ML1
Savini, G1
De Negri, A1
Simonelli, F1
Sadun, F1
Caporali, L1
Maresca, A1
Liguori, R1
Baruzzi, A1
Zeviani, M1

Trials

1 trial available for idebenone and Autosomal Dominant Optic Atrophy

ArticleYear
Idebenone treatment in patients with OPA1-mutant dominant optic atrophy.
    Brain : a journal of neurology, 2013, Volume: 136, Issue:Pt 2

    Topics: Adult; Child; Cohort Studies; Female; Follow-Up Studies; GTP Phosphohydrolases; Humans; Male; Middle

2013

Other Studies

2 other studies available for idebenone and Autosomal Dominant Optic Atrophy

ArticleYear
Idebenone increases chance of stabilization/recovery of visual acuity in OPA1-dominant optic atrophy.
    Annals of clinical and translational neurology, 2020, Volume: 7, Issue:4

    Topics: Adolescent; Adult; Antioxidants; Cohort Studies; Female; GTP Phosphohydrolases; Humans; Male; Middle

2020
A randomized, placebo-controlled trial of the benzoquinone idebenone in a mouse model of OPA1-related dominant optic atrophy reveals a limited therapeutic effect on retinal ganglion cell dendropathy and visual function.
    Neuroscience, 2016, Apr-05, Volume: 319

    Topics: Animals; Antioxidants; Blotting, Western; Dendrites; Disease Models, Animal; Female; GTP Phosphohydr

2016